top of page
OraLiva Gradient Backdrop.jpg

OraLiva Inc. in The News

News and press release information for OraLiva Inc. Stay informed and up to date with all of the latest information regarding this amazing new medical technology organization, making strides in the oral cancer community.

rs=w_400,cg_true,m.jfif
OraLiva_Torso-01-01.jpg

NYU Press Release

OraLiva Press Coverage

OraLiva Internal Press Release

Press Release:

October 28, 2023

OraLiva, INC has been selected to join the Endless Frontier Labs 2022-2023 cohort alongside 78 ground-breaking companies! We look forward to working with EFL mentors, NYU Stern MBA students, and the rest of the companies selected for the Life Sciences track.

 

“OraLiva leadership is thrilled to be selected as part of the top ~5% of promising companies that applied for this exclusive program. We hope to use this activity to accelerate the release of our AI linked cancer diagnostic technologies that allows a broad range of clinicians to identify early signs of cancer with clinically validated cyto-signatures”. [Quote from OraLiva Founder and NYU Professor, John T. McDevitt]

 

Endless Frontier Labs (EFL), a program for early-stage science and technology-based startups at New York University Stern School of Business, is structured to optimize each startup’s chance of scaling into a successful company through a goals-based mentoring process. EFL mentors are experienced entrepreneurs who have built and exited successful companies, world-renowned scientists and technical experts, and well-known venture capital and angel investors.

 

Over nine months, EFL mentors work with admitted founders to set goals for the startups to accomplish and act as an informal advisory board to guide founders on how best to scale their businesses. Startups making progress are able to attract financing from investors in the program.   

 

Consistent with its mission as a non-profit, EFL is a founders-first program and charges no equity or fees from participating startups. No NYU affiliation or relocation to NYC is required to participate. The program is appropriate for founders from around the world seeking deep connections to the thriving New York ecosystem or U.S. markets.

 

“Our mission is to bridge the gap between science and markets.  We believe business strategy, validation by scientific peers, and connections to investors are critical for the successful commercialization of scientific breakthroughs. To that end, EFL provides founders access to an unparalleled network of business coaches, scientists, investors, and Stern MBA students to help transform their ideas into high-growth businesses,” said NYU Stern Professor Deepak Hegde, Founding Director of EFL.

 

More About EFL

Endless Frontier Labs (EFL) is a nine-month program at NYU Stern for early-stage science- and technology-based startups. Startup founders are advised by serial entrepreneurs, investors, and technical mentors to accomplish individualized business goals at eight-week intervals. These goals are designed to maximize each startup’s chance of growing into a high-growth business.  Startups that fail to make progress can be cut from the program at mentor discretion in order to optimize resources for startups that are excelling. Those that meet their goals are likely to attract investment from EFL mentors, as well as from one of the many venture capital firms that are represented in the program. While companies in the EFL program do not require an NYU affiliation to participate, all companies will benefit from access to and support from NYU scientists and Stern MBA students. Startups can also benefit from access to several in-kind services from EFL’s corporate partners, such as advice on intellectual property issues and related matters from global law firm Greenberg Traurig, LLP and server credits from Amazon Web Services. As EFL is a non-profit academic initiative of New York University’s Stern School of Business, EFL does not take equity or collect fees from startups. Further information and FAQ can be found on EFL’s website and follow us on LinkedIn, and Twitter for regular updates.

 

About OraLiva

OraLiva Inc. is an exciting newly formed diagnostics company that has developed the first AI-linked cytomics-on-a-chip capability for use at point-of-care.  This transformative new technology has the potential to allow for a broad range of clinicians to identify early signs of cancer using clinically validated cyto-signatures. OraLiva’s proprietary Oral ONC-InCyt technology allows for multiparameter single-cell measurements to be completed in near real-time. The approach has been validated by one of the largest prospective clinical studies of potentially malignant oral lesions ever completed. The lab in a kit and algorithm are designed to augment and improve upon current diagnostic capabilities, including flow cytometry, tissue biopsy/histology and lab-based manual cytology tests, which are less accurate and more costly to run per test. This award-winning programmable diagnostics platform was developed through partnership with the McDevitt laboratory at NYU. Oraliva’s Oral ONC-InCyt  technology provides noninvasive, painless, reliable, clinically validated Al linked diagnostics for the detection of oral cancer and oral dysplasia. Oraliva plans to initially offer the Oral ONC-InCyt technology as a Laboratory Service through its NC Lab. 

bottom of page